Bristol-Myers Squibb, Nordic Bioscience to develop NASH biomarkers

Bristol-Myers Squibb and Nordic Bioscience have entered an agreement to develop biomarker technology for diagnosing and monitoring fibrotic diseases such as nonalcoholic steatohepatitis, according to a press release.

“Addressing the significant need for better diagnostic and monitoring tools in fibrotic diseases is a key element of Bristol-Myers Squibb’s fibrosis strategy to help patients suffering from these debilitating conditions,” Mike Burgess, head of cardiovascular, fibrosis and immunoscience development at Bristol-Myers Squibb, said in the release. “We continue to invest in innovative approaches to develop more precise methods to diagnose disease and monitor progression and we are pleased to partner with Nordic Bioscience and leverage their vast experience in biomarker development.”

The companies will collaborate to develop translational biomarkers and diagnostics for NASH evaluation in both pre-clinical models and clinical settings.

Reference: www.bms.com; www.nordicbioscience.com